Financial

Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical Programs and Corporate Highlights on Wednesday, February 7, 2018

Conference Call and Webcast To be Held Wednesday, February 7, 2018 at 4:30pm Eastern Time   NEW YORK, NY – February 5, 2017 – Anavex Life Sciences Corp., (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including Alzheimer’s disease, other central nervous…

Central Nervous System Noble

Anavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference

NEW YORK – January 24, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive…

Anavex Life Sciences Financial results

Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs

Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK – December 11, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases…

Multiple sclerosis

Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017

ANAVEX®2-73 Shown to Protect and Repair Myelin Forming Cells NEW YORK, NY – October 27, 2017 – Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types…